Bellerophon announces license agreement for commercialization of INOpulse

Bellerophon Therapeutics announced that it has entered into a license agreement for the development and commercialization of INOpulse with Baylor BioSciences, a life sciences company dedicated to the development and commercialization of innovative medical products for Greater China. Under the terms of the license agreement, Bellerophon will receive a license payment of $6M, payable within 90 days subject to certain closing conditions set forth in the agreement. Additionally, Bellerophon is entitled to royalties of 5% on net sales resulting from all of the licensed INOpulse indications within Greater China. Baylor BioSciences will receive exclusive rights to develop and commercialize INOpulse within Greater China for diseases associated with pulmonary hypertension, including the lead indication of fibrotic interstitial lung disease, as well as PH-Sarcoidosis and PH-COPD. "We are delighted to partner with Baylor BioSciences to potentially bring INOpulse to patients in Greater China," said Peter Fernandes, Bellerophon’s Chief Executive Officer. "If approved, INOpulse has the potential to become the first therapy to treat a broad fILD population that includes patients at low-, intermediate- and high-risk of pulmonary hypertension. We believe that this agreement further validates the potential of INOpulse to address the significant unmet need for therapies that improve activities of daily living and quality of life in patients with fILD, as well as other underserved diseases, including PH-Sarcoidosis and PH-COPD. Importantly, this agreement enables us to gain access to one of the largest markets globally, while strengthening our balance sheet."